1.17
-0.09(-7.14%)
Currency In USD
| Previous Close | 1.26 |
| Open | 1.35 |
| Day High | 1.35 |
| Day Low | 1.06 |
| 52-Week High | 412.5 |
| 52-Week Low | 1.06 |
| Volume | 11.66M |
| Average Volume | 399,360 |
| Market Cap | 651,445 |
| PE | -0.02 |
| EPS | -53.03 |
| Moving Average 50 Days | 6.74 |
| Moving Average 200 Days | 24.64 |
| Change | -0.09 |
If you invested $1000 in Profusa, Inc. Common Stock (PFSA) since IPO date, it would be worth $7.72 as of February 26, 2026 at a share price of $1.17. Whereas If you bought $1000 worth of Profusa, Inc. Common Stock (PFSA) shares 6 months ago, it would be worth $36.26 as of February 26, 2026 at a share price of $1.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance
GlobeNewswire Inc.
Feb 19, 2026 1:30 PM GMT
With strong underlying market demand, European distributor and expert physician customer purchase orders are being received by the Company as its 2026 revenue guidance range increases to $1.5 million - $3 million BERKELEY, Calif, Feb. 19, 2026 (GLO
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
GlobeNewswire Inc.
Feb 12, 2026 9:30 PM GMT
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous oxygen monitoring products for hi
Profusa Announces 1-for-75 Reverse Stock Split
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an